Skip to main content

Sangeeta Sule

Dr Sangeeta Sule received her undergraduate education at Tulane University and her MD degree from Baylor College of Medicine. She continued at Baylor for her internship and residency in Internal Medicine and Pediatrics. Sangeeta then completed her fellowship training in Rheumatology at Johns Hopkins University and joined then joined the faculty where she was Associate Professor. In 2008, she obtained a PhD in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health. In 2018, Sangeeta became Chief of Rheumatology at Children’s National Medical Center and Associate Professor of Pediatrics at George Washington University School of Medicine and Health Sciences. Sangeeta’s research interests focus on clinical outcomes in pediatric lupus and arthritis and her work has been published in multiple peer-reviewed journals. She has also completed advance training in quality improvement and has been involved in projects for development and implementation of outcome measures in pediatric rheumatology.


Latest contributions from Sangeeta Sule

COVID-19 podcast

27-03-2020 | COVID-19 | Podcast | Audio

COVID-19: A pediatric rheumatologist’s perspective

Sangeeta Sule, from Children’s National Hospital in Washington, DC, USA, shares her experience of how the pediatric rheumatology community is adapting to the COVID-19 pandemic, including the use of telemedicine practices (9:06).

Children running (symbolic image with models)

24-03-2020 | Physical activity | Editorial | Article

Exercise recommendations for children with juvenile idiopathic arthritis

Sangeeta Sule discusses the current recommendations for physical activity in children with juvenile idiopathic arthritis.

Sangeeta Sule

14-11-2019 | Juvenile idiopathic arthritis | Video | Article

Expert commentary: Safety and efficacy of tofacitinib in juvenile idiopathic arthritis

Sangeeta Sule gives a pediatric rheumatologist’s view on a trial looking at tofacitinib for the treatment  of polyarticular juvenile idiopathic arthritis and the potential implementation of the results in the clinic (2:55).

07-05-2019 | Systemic lupus erythematosus | Article

Editorial board comment

Comment on: Belimumab approved for pediatric lupus in the USA